Aviva PLC lessened its holdings in Medifast, Inc. (NYSE:MED – Get Rating) by 34.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,418 shares of the specialty retailer’s stock after selling 4,440 shares during the quarter. Aviva PLC’s holdings in Medifast were worth $971,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of MED. Cambridge Investment Research Advisors Inc. grew its position in shares of Medifast by 4.5% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,488 shares of the specialty retailer’s stock worth $254,000 after purchasing an additional 64 shares in the last quarter. HighTower Advisors LLC grew its holdings in Medifast by 3.4% during the 1st quarter. HighTower Advisors LLC now owns 2,600 shares of the specialty retailer’s stock valued at $443,000 after buying an additional 86 shares in the last quarter. Boston Partners raised its position in shares of Medifast by 2.4% during the fourth quarter. Boston Partners now owns 4,655 shares of the specialty retailer’s stock valued at $537,000 after buying an additional 107 shares during the last quarter. Captrust Financial Advisors lifted its holdings in shares of Medifast by 16.8% in the second quarter. Captrust Financial Advisors now owns 757 shares of the specialty retailer’s stock worth $138,000 after buying an additional 109 shares in the last quarter. Finally, Great West Life Assurance Co. Can lifted its holdings in shares of Medifast by 1.1% in the first quarter. Great West Life Assurance Co. Can now owns 10,253 shares of the specialty retailer’s stock worth $1,797,000 after buying an additional 112 shares in the last quarter. 86.03% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
MED has been the topic of a number of research reports. DA Davidson reduced their price target on shares of Medifast from $94.00 to $71.00 in a report on Tuesday, May 2nd. StockNews.com assumed coverage on Medifast in a research report on Thursday. They issued a “hold” rating on the stock.
Medifast Stock Down 1.2 %
Medifast (NYSE:MED – Get Rating) last released its quarterly earnings results on Monday, May 1st. The specialty retailer reported $3.67 EPS for the quarter, topping the consensus estimate of $2.40 by $1.27. Medifast had a return on equity of 106.70% and a net margin of 9.27%. The company had revenue of $349.00 million during the quarter, compared to analyst estimates of $319.50 million. During the same quarter last year, the business posted $3.59 earnings per share. The firm’s revenue was down 16.4% on a year-over-year basis. On average, analysts expect that Medifast, Inc. will post 8.86 earnings per share for the current year.
Medifast Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, May 9th. Investors of record on Tuesday, March 28th were issued a dividend of $1.65 per share. This represents a $6.60 annualized dividend and a yield of 7.34%. The ex-dividend date was Monday, March 27th. This is a positive change from Medifast’s previous quarterly dividend of $1.64. Medifast’s dividend payout ratio is presently 51.68%.
Insider Buying and Selling
In other news, Director Jeffrey J. Brown bought 754 shares of Medifast stock in a transaction dated Friday, May 5th. The shares were acquired at an average price of $89.74 per share, with a total value of $67,663.96. Following the completion of the purchase, the director now owns 37,695 shares in the company, valued at approximately $3,382,749.30. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Medifast news, Director Scott Schlackman sold 2,200 shares of the business’s stock in a transaction that occurred on Friday, March 10th. The stock was sold at an average price of $108.68, for a total transaction of $239,096.00. Following the completion of the transaction, the director now owns 7,280 shares in the company, valued at $791,190.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey J. Brown bought 754 shares of the business’s stock in a transaction dated Friday, May 5th. The shares were acquired at an average cost of $89.74 per share, for a total transaction of $67,663.96. Following the purchase, the director now owns 37,695 shares of the company’s stock, valued at approximately $3,382,749.30. The disclosure for this purchase can be found here. 2.30% of the stock is owned by corporate insiders.
Medifast, Inc engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups.
- Get a free copy of the StockNews.com research report on Medifast (MED)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding MED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medifast, Inc. (NYSE:MED – Get Rating).
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.